Targeted treatments to improve stem cell outcome: Old and new drugs

Bone Marrow Transplantation

Volumn 40, Issue 12, 2007, Pages 1129-1137

  Raab, M S ^a   Breitkreutz, I ^a   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; MAINTENANCE THERAPY; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHOCOMELIA; PRIORITY JOURNAL; RASH; REVIEW; SOMNOLENCE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DELIVERY SYSTEMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 36649030794     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705829     Document Type: Review

References (75)

1. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183-196.
2. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
3. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434-2441.
4. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
5. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978.
6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
7. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875-882.
8. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003; 40 (Suppl 4): 3-7.
9. Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma. Hematol J 2000; 1: 186-189.
10. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
11. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
12. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404-408.
13. Blade J, Esteve J, Rosinol L, Perales M, Montoto S, Tuset M et al. Thalidomide in refractory and relapsing multiple myeloma. Semin oncol 2001; 28: 588-592.
14. Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001; 12: 987-990.
15. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87 408-414.
16. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide; long-term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909-914.
17. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34-39.
18. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
19. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. M. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
20. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
21. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-117.
22. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/ refractory multiple myeloma. Leukemia 2004; 18: 856-863.
23. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846-3848.
24. Palumbo A, Bringhen S, Caravrita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367 825-831.
25. Facon T. Advances in the treatment of elderly patients with multiple myeloma. Clin Adv Hematol Oncol 2006; 4: 501-502.
26. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
27. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2006; 24: 431-436.
28. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
29. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
30. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
31. Breitkreutz I, Lokhorst HM, Raab MS, Holt BV, Cremer FW, Herrmann D et al. Thalidomide in newly diagnosed multiple myeloma: Influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294-1299.
32. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F; et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
33. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band q121 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724-1732.
34. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated i4rith immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-982.
35. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170-8176.
36. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
37. Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006; 106: 2171-2180.
38. Sun K, Welniak LA, Panoskatslis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120-8125.
39. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22 3269-3276.
40. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.
41. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924,
42. Hegenbart U, Schonland SO, Moehler TM, Benner A, Gerull S, Goerner M et al. Polychemotherapy in combination with thalidomide followed by autologous or allogeneic transplantation for rescue after autograft or induction therapy failure in patients with multiple myeloma. ASH Annual Meeting Abstracts 2006; 108: 3018.
43. van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415-3416.
44. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: A retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35: 165-169.
45. Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361-3363.
46. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: Activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32: 165-170.
47. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
48. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001; 15: 1950-1961.
49. Lentzsch S, Le Blanc R, Podar K, Davies F, Lin B, Hideshima T et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41-44.
50. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002; 99: 4525-4530.
51. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
52. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
53. Weber D, Wang M, Chen CI, Belch AR, Stadtmauer EA, Niesvizky R et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. ASH Annual Meeting Abstracts 2006; 108: 3547.
54. Dimopoulos MA, Anagnostopoulos A, Prince M, Harousseau JL, Dmoszynska A, Hellmann A et al. Lenalidomide (Revlimid) combination with dexamethasone (Dex) is more effective than Dex alone in patients with relapsed or refractory multiple myeloma. Haematologica 2006; 91 194.
55. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
56. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust SR et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: Response to therapy, time to progression, and survival. ASH Annual Meeting Abstracts 2006; 108: 798.
57. Palumbo A, Falco P, Falcone A, Corradini P, Di Raimondo F, Giuliani N et al. Oral Revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter phase I/II study. ASH Annual Meeting Abstracts 2006; 108: 800.
58. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole D, Greipp PR. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern cooperative oncology group. ASH Annual Meeting Abstracts 2006; 108: 799.
59. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole D, Williams ME et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2007. ASCO Annual Meeting Proceedings Part I 25, LBA8025. 2007; 25 (Suppl): 18.
60. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10: 361-369.
61. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
62. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
63. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
64. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172.
65. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783.
66. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 2006; 91: 1498-1505.
67. Rosinol L, Oriol A, Mateos MV, Sureda A, Diaz-Mediavilla J, Alegre A et al. Alternating bortezomib and dexamethasone as induction regimen prior to autologous stem-cell transplantation in newly diagnosed younger patients with multiple myeloma: Results of a PETHEMA phase II trial. ASH Annual Meeting Abstracts 2006; 108: 3086.
68. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple mycloma. Br J Haematol 2005; 129: 755-762.
69. Harousseau JL, Marit G, Caillot D, Casassus P, Facon T, Mohty M et al. VELCADE/Dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): An interim analysis of the IFM 2005-01 randomized multicenter phase III trial. ASH Annual Meeting Abstracts 2006; 108: 56.
70. Schiller G, Sohn JP, Malone R, Bartone B, Habtemariam B, Paquette R et al. Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myelorna. ASH Annual Meeting Abstracts 2007; 108: 5433.
71. Knop S, Hebart H, Kunzmann V, Angermund R, Einsele H. Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma. ASH Annual Meeting Abstracts 2007; 108: 5099.
72. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006; 91: 837-839.
73. Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J et al. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment [in process citation]. Biol Blood Marrow Transplant 2007; 13: 479-499.
74. Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770-775.
75. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.